531 related articles for article (PubMed ID: 15824225)
41. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
[TBL] [Abstract][Full Text] [Related]
42. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study.
Arias L; Garcia-Arumi J; Ramon JM; Badia M; Rubio M; Pujol O
Ophthalmology; 2006 Dec; 113(12):2243-50. PubMed ID: 16996600
[TBL] [Abstract][Full Text] [Related]
43. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.
Rinaldi M; Semeraro F; Chiosi F; Russo A; Romano MR; Savastano MC; dell'Omo R; Costagliola C
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):529-539. PubMed ID: 27680013
[TBL] [Abstract][Full Text] [Related]
44. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study.
Ruamviboonsuk P; Tadarati M; Vanichvaranont S; Hanutsaha P; Pokawattana N
Br J Ophthalmol; 2010 Aug; 94(8):1045-51. PubMed ID: 20530656
[TBL] [Abstract][Full Text] [Related]
45. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy.
Ladd BS; Solomon SD; Bressler NM; Bressler SB
Am J Ophthalmol; 2001 Nov; 132(5):659-67. PubMed ID: 11704027
[TBL] [Abstract][Full Text] [Related]
46. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration.
Augustin AJ; Schmidt-Erfurth U
Am J Ophthalmol; 2006 Apr; 141(4):638-45. PubMed ID: 16564797
[TBL] [Abstract][Full Text] [Related]
47. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome.
Ruiz-Moreno JM; Montero JA; Barile S; Zarbin MA
Retina; 2006; 26(6):602-12. PubMed ID: 16829800
[TBL] [Abstract][Full Text] [Related]
48. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
Bashshur ZF; Schakal A; Hamam RN; El Haibi CP; Jaafar RF; Noureddin BN
Arch Ophthalmol; 2007 Oct; 125(10):1357-61. PubMed ID: 17923543
[TBL] [Abstract][Full Text] [Related]
49. Combined photodynamic therapy and intravitreal triamcinolone for nonsubfoveal choroidal neovascularization.
Spaide RF; Sorenson J; Maranan L
Retina; 2005 Sep; 25(6):685-90. PubMed ID: 16141854
[TBL] [Abstract][Full Text] [Related]
50. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration.
; Gilson MM; Bressler NM; Jabs DA; Solomon SD; Thorne JE; Wilson DJ
Ophthalmology; 2007 Sep; 114(9):1713-21. PubMed ID: 17822977
[TBL] [Abstract][Full Text] [Related]
51. Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization.
Lu F; Hu Z; Sinard J; Garen A; Adelman RA
Invest Ophthalmol Vis Sci; 2009 Aug; 50(8):3890-6. PubMed ID: 19357351
[TBL] [Abstract][Full Text] [Related]
52. Combination of verteporfin photodynamic therapy and ranibizumab: effects on retinal anatomy, choroidal perfusion and visual function in the protect study.
Kiss CG; Simader C; Michels S; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Dec; 92(12):1620-7. PubMed ID: 19029163
[TBL] [Abstract][Full Text] [Related]
53. Combined photodynamic therapy and intravitreal triamcinolone acetonide injection for neovascular age-related macular degeneration with pigment epithelium detachment.
Axer-Siegel R; Ehrlich R; Avisar I; Kramer M; Rosenblatt I; Priel E; Weinberger D
Ophthalmic Surg Lasers Imaging; 2006; 37(6):455-61. PubMed ID: 17152538
[TBL] [Abstract][Full Text] [Related]
54. Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.
Rishi P; Rishi E; Bhende M; Agarwal V; Vyas CH; Valiveti M; Bhende P; Rao C; Susvar P; Sen P; Raman R; Khetan V; Murali V; Ratra D; Sharma T
Br J Ophthalmol; 2016 Oct; 100(10):1337-40. PubMed ID: 26792945
[TBL] [Abstract][Full Text] [Related]
55. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment.
Krzystolik MG; Afshari MA; Adamis AP; Gaudreault J; Gragoudas ES; Michaud NA; Li W; Connolly E; O'Neill CA; Miller JW
Arch Ophthalmol; 2002 Mar; 120(3):338-46. PubMed ID: 11879138
[TBL] [Abstract][Full Text] [Related]
56. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lee GK; Luk FO; Lam DS
Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
[TBL] [Abstract][Full Text] [Related]
57. Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab.
Byon IS; Kwon HJ; Kim SI; Shin MK; Park SW; Lee JE
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):534-41. PubMed ID: 25423633
[TBL] [Abstract][Full Text] [Related]
58. Photodynamic therapy with verteporfin combined with intravitreal injection of bevacizumab for exudative age-related macular degeneration.
Aggio FB; Melo GB; Höfling-Lima AL; Eid Farah M
Acta Ophthalmol Scand; 2006 Dec; 84(6):831-3. PubMed ID: 17083553
[No Abstract] [Full Text] [Related]
59. [Photodynamic therapy with verteporfin in occult choroidal neovascularization in age-related macular degeneration].
Kürzinger GR; Stender B; Lang GK; Lang GE
Klin Monbl Augenheilkd; 2010 Jun; 227(6):501-6. PubMed ID: 20349399
[TBL] [Abstract][Full Text] [Related]
60. Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis).
Miller JW
Trans Am Ophthalmol Soc; 2008; 106():357-82. PubMed ID: 19277246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
